📈
📈 Business
How Eli Lilly outmaneuvered Novo Nordisk and took over the GLP-1 weight-loss market
Denmark's Novo Nordisk created the world's most lucrative new drug with Ozempic, but America's Eli Lilly outmaneuvered it and seized control of the GLP-1 weight-loss drug market. The analysis examines how Lilly strategically gained the upper hand and what the shift means for Europe's ability to compete in the high-stakes global pharmaceutical economy. The case raises broader questions about whether Europe can keep pace with the United States in drug innovation.
Similar stories
Comments
No comments yet
Comments
No comments yet — be the first to weigh in 👇
No comments yet. Be the first!